Published in Stroke on June 25, 2013
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med (2010) 2.73
Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J Am Coll Cardiol (2013) 2.62
Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med (2009) 1.97
High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv (2013) 1.50
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. Thromb Haemost (2013) 1.42
Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol (2010) 1.39
Aspirin dose and ticagrelor benefit in PLATO: fact or fiction? Cardiology (2011) 1.39
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction. Cardiology (2015) 1.39
Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart (2013) 1.19
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation (2003) 1.14
Neuro-glial and systemic mechanisms of pathological responses in rat models of primary blast overpressure compared to "composite" blast. Front Neurol (2012) 1.10
Trimethylamine-N-Oxide and Heart Failure. J Am Coll Cardiol (2015) 1.09
Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc (2013) 1.09
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J (2010) 1.08
The molecular biology and pathophysiology of vascular calcification. Postgrad Med (2014) 0.99
Retracted Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis. Heart (2013) 0.96
Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther (2006) 0.94
Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol (2002) 0.92
Standardizing portion sizes may not benefit human or environmental health. Am J Public Health (2014) 0.91
Chlorthalidone versus hydrochlorothiazide. Ann Intern Med (2013) 0.87
Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? Am Heart J (2002) 0.86
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J (2003) 0.86
Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am Heart J (2011) 0.86
Thirty-day readmission rates after PCI in a metropolitan center in Europe: incidence and impact on prognosis. J Cardiovasc Med (Hagerstown) (2015) 0.86
Endothelial progenitor cells and left ventricle function in patients with acute myocardial infarction: potential therapeutic considertions. Am J Ther (2012) 0.85
Knowledge, attitude and perception of antiplatelet therapy among dentists in Central Eastern Turkey. World J Cardiol (2012) 0.84
Omega-3 fatty acids: a growing ocean of choices. Curr Atheroscler Rep (2014) 0.83
Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry. J Thromb Thrombolysis (2010) 0.82
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis (2008) 0.82
Vitamin D and atherosclerosis. Curr Opin Cardiol (2014) 0.82
Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes. Diabetes (2013) 0.82
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med (2013) 0.82
Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol (2003) 0.82
Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol (2004) 0.82
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology (2013) 0.81
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost (2012) 0.81
Impact of moderate blast exposures on thrombin biomarkers assessed by calibrated automated thrombography in rats. J Neurotrauma (2013) 0.81
Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis (2003) 0.80
The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome. Cardiology (2013) 0.80
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol (2002) 0.80
Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. J Clin Pharmacol (2006) 0.80
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. Cardiology (2015) 0.80
Delays of event adjudication in the TRITON trial. Cardiology (2010) 0.80
Benefits and risks of aspirin use. JAMA (2012) 0.80
Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. Scand J Urol Nephrol (2010) 0.79
The big ones that got away: omega-3 meta-analysis flawed by excluding the biggest fish oil trials. Arch Intern Med (2012) 0.79
The "clopidogrel resistance" trap. Am J Cardiol (2007) 0.78
Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. Circ Res (2006) 0.78
Carvedilol and spirulina may provide important health protection to smokers and other nicotine addicts: a call for pertinent research. Mo Med (2015) 0.78
Realistic assessment of drug-induced adverse events: a double-edged sword. Am J Med (2010) 0.78
Response to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary Syndromes. Cardiology (2015) 0.77
Aldosterone antagonists: evidence-based yet underutilized effective heart failure therapy. Congest Heart Fail (2013) 0.77
The challenge of monitoring platelet response after clopidogrel. Eur Heart J (2008) 0.77
Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. J Invasive Cardiol (2002) 0.77
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology (2011) 0.77
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology (2013) 0.77
Troponin I and D-Dimer for Discriminating Acute Pulmonary Thromboembolism from Myocardial Infarction. Cardiology (2016) 0.77
Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiol (2014) 0.76
The FDA prasugrel review: adjudication of myocardial infarction controversy. Cardiology (2009) 0.76
Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. Clin Physiol Funct Imaging (2002) 0.76
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol (2012) 0.76
Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. Expert Opin Pharmacother (2006) 0.76
Adhesion molecules, platelet activation, and cardiovascular risk. Am Heart J (2002) 0.76
Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. Am J Ther (2011) 0.76
Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology (2007) 0.76
Red yeast rice for dysipidemia. Mo Med (2013) 0.76
Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis (2002) 0.76
Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med (Hagerstown) (2015) 0.76
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J (2003) 0.76
Aspirin 50 versus 100 mg: a case of wrong dosing. Am J Cardiol (2011) 0.75
Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost (2011) 0.75
Reply: Effects of habitual coffee consumption on vascular function. J Am Coll Cardiol (2013) 0.75
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news. Cardiology (2008) 0.75
Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology (2013) 0.75
Dyspnoea after AZD6140: safety first? Eur Heart J (2006) 0.75
Switching thienopyridines: hypothetical versus real risks. J Am Coll Cardiol (2008) 0.75
Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. Altern Ther Health Med (2015) 0.75
Exploring PLATO-USA paradox and CURRENT-OASIS 7 trials reveals the benefit of higher aspirin dose. Am J Ther (2015) 0.75
Prasugrel, clopidogrel, and combining Swedish apples with American oranges. Eur Heart J (2006) 0.75
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma. Eur Heart J (2007) 0.75
Neutralizing the adverse prognosis of coronary artery calcium. Mayo Clin Proc (2013) 0.75
Von Willebrand factor for predicting bleeding and mortality real deal or another failed biomarker? J Am Coll Cardiol (2011) 0.75
The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. Cardiol Res Pract (2013) 0.75
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 0.75
Cilostazol--a forgotten antiplatelet agent, but does it even matter? JACC Cardiovasc Interv (2013) 0.75
Aggressive antiplatelet strategies: time to reconsider? Eur Heart J (2007) 0.75
Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? Stroke (2012) 0.75
Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther (2015) 0.75
Impact of valve surgery on serum osteopontin levels in patients with mitral regurgitation. Cardiology (2015) 0.75
Asymptomatic Pulmonary Embolism after Ablation. Cardiology (2016) 0.75
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy. Nephron (2016) 0.75
Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. Ther Adv Cardiovasc Dis (2013) 0.75
Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO. Cardiology (2012) 0.75
The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke. Curr Treat Options Cardiovasc Med (2006) 0.75
Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates. Int J Cardiol (2012) 0.75
Excessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger? Am J Ther (2015) 0.75